 | Up a level |
Journal Article
Bos, M., Gardizi, M., Heukamp, L. C., Merkelbach-Bruse, S., Schildhaus, H. -U., Scheffler, M., Nogova, L., Mattonet, C., Serke, M., Randerath, W. J., Gerigk, U., Bruemmendorf, T. H., Krueger, S., Panse, J., Kaminski, B., Reiser, M., Buettner, R. and Wolf, J. (2014). The Network Genomic Medicine: A prospective comprehensive molecular screening network for implementation of personalized lung cancer therapy. Oncol. Res. Treat., 37. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262
Bos, M., Gardizi, M., Heukamp, L. C., Schildhaus, H. -U., Merkelbach-Bruse, S., Nogova, L., Scheffler, M., Serke, M., Schulz, H., Krueger, S., Bruemmendorf, T. H., Panse, J., Schmitz, S., Gerigk, U., Randerath, W. J., Ko, Y. D., Kambartel, K., Huenerlituerkoglu, A. -N., Buettner, R. and Wolf, J. (2014). A retrospective analysis of overall survival of ALK translocation - and of EGFR mutation positive NSCLC patients treated with and without personalized therapy. Oncol. Res. Treat., 37. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262
Ceccon, G. S., Werner, J., Ruge, M., I, Goldbrunner, R., Celik, E., Baues, C., Deckert, M., Brunn, A., Buttner, R., Golla, H., Nogova, L., Schlamann, M., Kabbasch, C., Ruess, D., Hampl, J., Wollring, M., Bauer, E. K., Tscherpel, C., Fink, G. R., Langen, K. and Galldiks, N. (2022). Impact of FET PET on multidisciplinary neurooncological tumor board decisions in patients with brain tumors. Neuro-Oncology, 24. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866
Fischer, R. N., George, J., Scheel, A., Schloesser, H., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kern, J. K., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Michels, S., Nogova, L., Riedel, R., Weber, J-P., Buettner, R., Thomas, R. and Wolf, J. (2022). BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort. Ann. Oncol., 33 (7). S. S1025 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Glaser, M., Von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Wompner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A. K., Fischer, R. N., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buttner, R., Wolf, J. and Scheffler, M. (2022). The biological effect of small-scale ROS1 aberrations: An in silico analysis. Ann. Oncol., 33 (7). S. S1327 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J. and Scheffler, M. (2022). ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics. Ann. Oncol., 33. S. S56 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R. N., Riedel, R., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J. and Scheffler, M. (2022). Small-scale ROS1 aberrations: Functional impact and therapeutic potential. Ann. Oncol., 33 (8). S. S1386 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Koenig, K., Peifer, M., Bos, M., Nogova, L., Merkelbach-Bruse, S., Stamm, K., Henkel, T., Thomas, R., Wolf, J., Buettner, R. and Heukamp, L. (2014). High throughput parallel amplicon sequencing of common driver mutations from FFPE lung cancer samples in molecular pathological routine diagnostics for a regional health care provider network. Oncol. Res. Treat., 37. S. 31 - 33. BASEL: KARGER. ISSN 2296-5262
Kron, A., Scheffler, M., Ihle, M., Michels, S., Sueptitz, J., Prang, D., Jakobs, F., Nogova, L., Fischer, R. N., Eisert, A. K., Riedel, R., Kron, F., Hillmer, A., Loges, S., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2022). EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB). Ann. Oncol., 33 (7). S. S1006 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Meissner, A., Gutsche, R., Galldiks, N., Kocher, M., Junger, S., Eich, M., Nogova, L., Schmidt, N., Ruge, M., Goldbrunner, R., Proescholdt, M., Grau, S. and Lohmann, P. (2022). RADIOMICS FOR THE NON-INVASIVE ASSESSMENT OF THE PDL-1 EXPRESSION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER BRAIN METASTASES. Neuro-Oncology, 24. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866
Nogova, L., Gardizi, M., Bos, M., Scheffler, M., Papachristou, I., Woempner, C., Heukamp, L., Schildhaus, H. -U., Fuhr, U., Sos, M., Eberhardt, W., Wiesweg, M., Schmid, K. W., Schuler, M., Thomas, R., Buettner, R. and Wolf, J. (2014). TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262
Nogova, L., Mattonet, C., Gardizi, M., Scheffler, M., Bos, M., Woempner, C., Toepelt, K., Heukamp, L., Suleiman, A., Frechen, S., Soergel, F., Fuhr, U., Schnell, R., Katay, I., Behringer, D., Geist, T., Kaminski, B., Eichstaedt, M., Tummes, D., Buettner, R. and Wolf, J. (2014). SORAVE: Sorafenib and everolimus for patients with solid tumors and with KRAS mutated NSCLC - results of a phase I study. Oncol. Res. Treat., 37. S. 32 - 33. BASEL: KARGER. ISSN 2296-5262
Scheffler, M., Bos, M., Sos, M., Nogova, L., Gardizi, M., Mattonet, C., Papachristou, I., Kahraman, D., Kobe, C., Lammertsma, A., Boellaard, R., Persigehl, T., Heukamp, L., Buettner, R., Elter, T., Toepelt, K., Engel-Riedel, W., Stoelben, E., Neumaier, B., Dietlein, M., Zander, T. and Wolf, J. (2014). MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET and DCE-MRI for early prediction of efficacy in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262
Scheffler, M., Gardizi, M., Bos, M., Heukamp, L., Koenig, K., Serke, M., Nogova, L., Toepelt, K., Stoelben, E., Engel-Riedel, W., Randerath, W., Kaminsky, B., Panse, J., Zander, T., Buettner, R. and Wolf, J. (2014). Clinical and Molecular Characteristics of Non-Small Cell Lung Cancer Patients Harboring PIK3CA Mutations. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262
Scheffler, M., Gardizi, M., Bos, M., Nogova, L., Papachristou, I., Persigehl, T., Dietlein, F., Zander, T. and Wolf, J. (2014). BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination. Oncol. Res. Treat., 37. S. 131 - 132. BASEL: KARGER. ISSN 2296-5262